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Abstract The 14-3-3 protein test has been shown to
support the clinical diagnosis of sporadic Creutzfeldt-Jakob
disease (CJD) when associated with an adequate clinical
context, and a high differential potential for the diagnosis
of sporadic CJD has been attributed to other cerebrospinal
ﬂuid (CSF) proteins such as tau protein, S100b and
neuron speciﬁc enolase (NSE). So far there has been only
limited information available about biochemical markers
in genetic transmissible spongiform encephalopathies
(gTSE), although they represent 10–15% of human TSEs.
In this study, we analyzed CSF of 174 patients with gTSEs
for 14-3-3 (n = 166), tau protein (n = 78), S100b
(n = 46) and NSE (n = 50). Levels of brain-derived pro-
teins in CSF varied in different forms of gTSE. Biomarkers
were found positive in the majority of gCJD (81%) and
insert gTSE (69%), while they were negative in most cases
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DOI 10.1007/s00415-009-5163-xof fatal familial insomnia (13%) and Gerstmann-Stra ¨ussler-
Scheinker syndrome (10%). Disease duration and codon
129 genotype inﬂuence the ﬁndings in a different way than
in sporadic CJD.
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Introduction
The analysis of cerebrospinal ﬂuid (CSF) in patients with
suspected Creutzfeldt-Jakob disease (CJD) is an important
investigationforthedifferentialdiagnosisofCJDfromamong
other forms ofrapidprogressive dementia.The14-3-3protein
levelsareoftenincreasedintheCSFofsporadicCJDpatients,
and this test has therefore been included in the diagnostic
criteria for sporadic CJD when associated with an appropriate
clinical proﬁle [6, 31]. Increased levels of other brain-derived
proteins,suchastauprotein,S100borneuron-speciﬁcenolase
(NSE) have also been reported, but information on these
markersislimited[20,27].However,inmostgTSE,studiesof
CSF proteins report 14-3-3 test results only in gCJD with
E200K and V210I point mutations. Levels of brain-derived
proteinsarelowinGerstmann-Stra ¨ussler-Scheinkersyndrome
(GSS) and almost all fatal familial insomnia (FFI) patients
reported to date are negative for 14-3-3 [11, 15, 20, 30].
A very few data are available on the levels of the other
marker proteins in the CSF of patients with gTSEs, and no
analyses on factors inﬂuencing the percentage of elevated
levels have been done. In this paper, we perform such an
analysis on brain-derived proteins in patients having gTSE
with various mutations.
Methods
Patients and database
The study was performed in the framework of the EC-
supported multinational study on biomarkers in prion dis-
eases (CJD markers) [20].
A database was set up which included detailed data on
180 patients with genetic TSE, 61 (34%) gTSE patients
from Germany, 58 (32%) from Italy, 36 (20%) from Spain,
13 (7%) from the UK, 10 (5%) from Slovakia and 2 (1%)
from Switzerland.
The diagnoses of gTSE were carried out according to
recent surveillance criteria after PRNP analysis [11, 12].
For the estimation of the disease stage when the LP was
performed we divided the individual disease duration in
thirds and calculated the time of lumbar puncture according
to the ﬁrst third of the total duration of the disease (early
stage), the second (middle) or the third (advanced stage) of
the disease.
CSF tests
14-3-3 and other tests were performed according to pre-
viously described methods [20].
Statistical analyses
Differences in CSF levels of tau, S100b and NSE proteins
across the four genetic groups of gTSE were separately
assessed by the Kruskal–Wallis test, followed, when sta-
tistically signiﬁcant, by the Mann–Whitney test. Since
different techniques were employed for the determination
of S100b and NSE, we included in the quantitative
assessment levels only the results of the most frequently
used kits (Byk Sangtec for S100b and -Hofman LaRoche
for NSE).
We then calculated the percentage of positive results out
of the total for each CSF marker in the four genetic groups.
All samples were included in the analysis, since a positive
result was calculated according to the cut-off of the dif-
ferent techniques. The v
2 test was used to assess differ-
ences between categorical variables.
A multiple logistic regression model was used to
assess the effect of a set of clinically relevant variables
on the percentage of elevated levels of the different
biomarkers in gTSE patients. These were: type of disease
causing mutation, disease duration (in months), age at
onset (in years), disease stage when the lumbar puncture
was performed (during the ﬁrst, second or third period of
disease duration), and PRNP codon 129 genotype.
Country of patient and gender were entered as covariates.
Age at onset was categorized in four clinically mean-
ingful groups, with younger than 40 years as the refer-
ence group. Disease duration was categorized in two
groups (short and long duration), according to the median
survival time. Due to the small numbers of patients,
some of the statistical analyses were restricted to gCJD
groups or to the 14-3-3 test.
J. Gawinecka  I. Zerr (&)
National Reference Center for Transmissible Spongiform
Encephalopathies, Department of Neurology,
Georg-August-University Go ¨ttingen, Robert-Koch-Str. 40,
37075 Go ¨ttingen, Germany
e-mail: epicjd@med.uni-goettingen.de
C. M. van Duijn
Department of Epidemiology and Biostatistics,
Erasmus University Medical Center Rotterdam, PO Box 1738,
3000 DR Rotterdam, The Netherlands
e-mail: c.vanduijn@erasmusmc.nl
J Neurol (2009) 256:1620–1628 1621
123Results
General description
Demographic and clinical information on gTSE cases is
given in Table 1. A deﬁnite neuropathological diagnosis
was available in 52% of the cases, ranging from more than
87% of FFI to 22% of GSS patients, while in 47% of gCJD
autopsy was not performed. Data on the polymorphic
codon 129 of PRNP were available in 86% of all cases. For
some patients the only available information was about
PRNP with no information on codon 129 genotype. The
majority of gTSE patients were either homozygous for
methionine (MM, 58%) or heterozygous (MV, 36%), only
a few were homozygous for valine (6%). In a few cases,
where the PrP
Sc typing was available, it was invariable
PrP
Sc type I pattern.
Quantitative levels of brain-derived proteins
The CSF concentrations of tau protein ranged from 70.0 to
35,440.0 pg/ml (median 6,255.5 pg/ml) in the gCJD group,
from 75.0 to 20,370.0 pg/ml (median 2,354.0 pg/ml) in the
insert gTSE group, from 296.0 to 1,698.0 pg/ml (median
675.0pg/ml)intheGSSgroup,andfrom97.0to4,126.0 pg/ml
(median 464.5 pg/ml) in the FFI group (Fig. 1a). CSF levels
oftauproteinsigniﬁcantlydifferinthefourgroupsofgTSEs
(p\0.001,Kruskal–Wallistest),butdidnotvarywithinthe
gCJD group of patients (p = 0.13).
The median CSF concentrations of S100b protein were
above the cut-off level in all groups but one (FFI), ranging
from 1.0 to 16.0 ng/ml in gCJD (median 9.0 ng/ml), from
3.0 to 17.0 ng/ml in insert gTSE (median 11.0 ng/ml), and
from 1.0 to 6.0 ng/ml in FFI (median 3.0 ng/ml), Fig. 1b.
The only GSS patient tested for S100b protein had a CSF
concentration of 23.0 ng/ml. Statistical analysis showed a
signiﬁcant difference among the three groups (p = 0.002,
Kruskal–Wallis test).
The CSF concentrations of NSE protein ranged from
15.0 to 140.0 ng/ml (median 38.5 ng/ml) in only 10 gCJD
patients where it was tested, from 10.0 to 190.0 ng/ml
(median 17.0 ng/ml) in insert gTSE (n = 5), and from 9.0
to 16.0 ng/ml (median 12.5 ng/ml) in FFI (n = 2). The
GSS patient tested for NSE protein had a CSF concentra-
tion of 13.0 ng/ml. Difference in CSF levels of NSE pro-
tein within the four groups of gTSE patients did not reach
signiﬁcance (p = 0.08, Kruskal–Wallis test) (Fig. 1c).
Abnormal cerebrospinal ﬂuid ﬁndings in gTSEs
14-3-3
There was a statistically signiﬁcant difference in the rate of
elevated 14-3-3 levels among the four groups of gTSEs,
(p\0.001), see Table 2. A 14-3-3 positive test was pres-
ent in the majority of gCJD patients, irrespective of the
mutation they carried (R208H, V203I, E211Q, T188K, and
R148H). Thus, no signiﬁcant difference in percentage of
abnormal tests for 14-3-3 was found between E200K (81%)
andV210I (85%) or versus other forms of gCJD (72%).
Insert gTSE patients had also a high proportion of positive
tests (69%), while the 14-3-3 test was positive in only 10%
of GSS and in 13% of FFI cases.
Tau
A high rate of tau levels was found in gCJD and insert
gTSE groups, while in GSS only 40% of cases had tau
levels above the cut-off level of 1,300 pg. Only a single
FFI patient had abnormal tau levels in CSF (Table 2). The
levels of tau protein in the CSF were statistically different
in the four groups (p\0.001).
Table 1 Summary of clinical features of patients in the study
Forms of
gTSE
Number of cases
total (female
gender)
Percentage of
neuropatho-logically
conﬁrmed cases (n)
Age at onset,
years, median
(range)
Clinical duration,
months, median
(range)
Codon 129 polymorphism PrP type I
MM % (n)M V % ( n)V V % ( n)
gCJD 124 (68)
E200K 64 (37) 54.7 (35) 59 (29–86) 6 (0.43–34) 63.5 (33) 36.5 (19) 0.0 (0) 4/4
V210I 40 (19) 47.5 (19) 56.5 (43–87) 4 (1–31) 67.5 (27) 32.5 (13) 0.0 (0) 5/5
Other 20 (12) 28.6 (6) 65 (32–77) 6.5 (2–12) 37.5 (6) 31.3 (5) 31.3 (5) 3/3
FFI 23 (5) 87 (20) 56 (24–83) 12.5 (1–97) 60.9 (14) 39.1 (9) 0.0 (0)
GSS 10 (4) 22 (2) 50 (25–70) 80.5 (54–87) 30.0 (3) 60.0 (6) 10.0 (1)
A117V 1
P102L 8
P105L 1
Insert gTSE 17 (11) 52.9 (9) 63 (36–77) 11 (3–19) 46.7 (7) 33.3 (5) 20.0 (3) 1/1
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A similar distribution was observed for S100b values.
Elevated S100b levels were found in 87% of gCJD
and 77.8% of insert gTSE patients. These values
were lower in GSS and FFI patients. The differences
in the gTSE groups were statistically signiﬁcant,
(p = 0.002).
NSE
Only 64.3% of gCJD patients and 50% of insert gTSE
patients had NSE values above the cut-off level, while NSE
values were normal in GSS and FFI patients.
Effect of octapeptide repeats
The number of octapeptide repeats was inversely correlated
with the values of tau (Spearman q -0.51 (p = 0.036));
patients with high number of repeats (5 9 24) had low tau
levels. A similar trend was found for the 14-3-3 test;
patients with high number of repeats had low percentage of
abnormal tests : 1 9 24 (1/1); 3 9 24 (1/1); 4 9 24 (5/5);
5 9 24 (5/10) Fisher’s p value = 0.22.
Effects of patient characteristics on abnormal ﬁndings
The effect of clinical characteristics on percentage of
abnormal ﬁndings in gCJD patients was the age at disease
Fig. 1 a Box plots of CSF markers: total CSF tau protein levels in
gCJD (n = 52), GSS (n = 6), FFI (n = 18), and insert gTSE subjects
(n = 17). b Box plots of CSF S100b protein levels in gCJD (n = 15),
FFI (n = 13), and insert gTSE subjects (n = 9). c Box plots of CSF
levels of NSE in gCJD, FF1 (n = 13), and insert gTSE subjects
(n = 9). The line in the middle of the boxes represents the median.
The box extends from the 25th to the 75th percentile, bars indicate the
range of data distribution. The lines emerging from the box represent
the upper and lower adjacent values. Asterisks represent values more
extreme than the adjacent values referred to as outliers
J Neurol (2009) 256:1620–1628 1623
123onset (p = 0.014) and the PRNP codon 129 genotype (VV
vs. MV p = 0.043). Sensitivity of 14-3-3 was higher in old
patients compared to young ones (25.0% in patients
younger than 40 years, 83.9 in patients aged 40–60 years,
86.5% in 60–80 years and 100% in patients older than
80 years).
Regarding the percentage of abnormal ﬁndings in the
14-3-3 test in relation to the PRNP codon 129 genotype,
this was lower in gCJD patients homozygous for valine
than in heterozygous patients (VV vs. MV p = 0.043).
However, when we adjusted by type of mutation, this
statistical signiﬁcance was lost. Although the 14-3-3 test
performed worse in homozygous for methionine than in
heterozygous gCJD patients, this difference was not sig-
niﬁcant (v
2 test, p = 0.08) (Table 3). In E200K and V210I
patients, the 14-3-3 sensitivity was higher in heterozygous
(88.2 and 100%) than in methionine homozygous patients
(78.1 and 77.8%), but these differences did not reach any
signiﬁcance (Table 2).
Disease duration had no inﬂuence on 14-3-3 test
results (84.6% abnormal ﬁndings in patients with disease
duration below the median, and 87.3% in patients with
disease duration above the median survival time,
Table 3). In gCJD patients, there was no signiﬁcant
inﬂuence of the disease stage at the time of lumbar
puncture in relation to 14-3-3 results (p = 0.4) (100% in
te ﬁrst third of disease duration, 89% in the second third
and 82% in the last third, Table 3, as reported in sporadic
CJD [21].
Regarding the other CSF tests, there was a lower per-
centage of abnormal ﬁndings for the S100b test in gCJD
patients homozygous for methionine than in heterozygous
patients, while the opposite was found for tau and NSE
(Table 3), though the differences were not statistically
Table 2 Sensitivity (positive/
total) of CSF investigations by
forms of gTSE
14-3-3 Tau S100b NSE
gCJD 83.0 (97/117) 86.4 (38/44) 87.0 (20/23) 64.3 (18/28)
E200K 80.3 (49/61) 75.0 (15/20) 92.9 (13/14) 45.4 (5/11)
V210I 85.0 (34/40) 100 (13/13) 100 (4/4) 75.0 (6/8)
D178N-Val 33.3 (1/3) 100 (1/1) 0.0 (0/1) 100.0 (1/1)
R208H 100 (3/3) 100 (2/2) 100.0 (1/1)
V203I 100 (2/2)
E211Q 100 (2/2) 100 (2/2) 100 (1/1) 100 (1/1)
E196K 100 (2/2) 100 (3/3) 100 (2/2) 100 (3/3)
T188K 100 (2/2) 100 (1/1) 50.0 (1/2)
G114V 0.0 (0/1) 0.0 (0/1) 0.0 (0/1) 0.0 (0/1)
R148H 100 (1/1) 100 (1/1)
Insert gTSE 68.8 (11/16) 80.0 (12/15) 77.8 (7/9) 50.0 (4/8)
GSS 10.0 (1/10) 40.0 (2/5) 50.0 (2/4) 0.0 (0/2)
A117V 0.0 (0/1) 0.0 (0/1) 0.0 (0/1)
P102L 12.5 (1/8) 66.7 (2/3) 100 (2/2) 0.0 (0/2)
P105L 0.0 (0/1) 0.0 (0/1) 0.0 (0/1)
FFI 13.0 (3/23) 7.1 (1/14) 20.0 (2/10) 0.0 (0/12)
Stratiﬁcation by codon 129 genotype
E200K
MM 78.1 (25/32)
MV 88.2 (15/17)
VV 0.0 (0/0)
V210I
MM 77.8 (21/27) p = 0.06
MV 100.0 (13/13)
VV 0.0 (0/0)
Others
MM 100.0 (6/6)
MV 80.0 (4/5)
VV 50.0 (2/4)
1624 J Neurol (2009) 256:1620–1628
123signiﬁcant (p = 0.06 for tau, p = 0.92 for S100b, and
p = 0.24 for NSE, v
2 test).
Multivariate analysis, performed on all gTSE patients,
included as variables disease duration, age at onset, gender,
type of mutation and 129 genotype, and as covariates
gender and country of residence. This analysis revealed
that the type of mutation is the only variable that signiﬁ-
cantly inﬂuenced 14-3-3 test (p\0.004). Particularly, in
patients carrying the D178N-Met mutation (FFI), the per-
centage of abnormal ﬁndings of 14-3-3 decreased signiﬁ-
cantly in comparison to gCJD (p\0.007) and insert gTSE
(p\0.001). Interestingly, regarding the 129 codon poly-
morphism, 14-3-3 had lower percentage of abnormal tests
in patients homozygous for valine than in patients homo-
zygous for methionine or heterozygous, though no signif-
icant differences were found (crude p value = 0.5;
adjusted p value = 0.76). Table 4.
Multivariate analysis did not revealed any variables that
inﬂuenced tau, NSE or S100b levels in gTSE patients.
In all gTSE there was a statistically signiﬁcant negative
correlation between tau levels and disease duration
(Spearman q2 between duration and tau levels =- 0.52
(p\0.001). However, when the data were stratiﬁed by
diagnostic groups, numbers become too low and were not
signiﬁcant (only borderline for gCJD: r
2 =- 0.32,
p = 0.057).
Discussion
Data on brain-derived proteins in the CSF of patients with
genetic TSE are limited and conﬂicting results have been
reported, mostly because they are frequently based on
single case observations (see Table 4). In these reports,
sensitivity of biochemical markers in CSF is reported to be
lower than in sporadic CJD and this was explained in terms
of prolonged disease duration and relatively slow disease
progression. Because of the limited numbers of patients, no
detailed analysis on this topic is available.
In this study we provide data on four brain-derived
proteins in a cohort of patients with various forms of
genetic TSE. We found ﬁrm evidence for elevated con-
centrations of 14-3-3, tau, S100b and NSE in the CSF of
patients with genetic CJD, but not in FFI or GSS patients.
Of interest, the median concentrations for tau, S100b and
NSE were similar to those detected in sporadic CJD in
other studies [1, 16, 20]. In our previous study on sporadic
CJD, we reported median tau levels in the range of
Table 3 Sensitivity of tests in gCJD
Characteristics Number of 14-3-3
positive patients/total
Number of tau positive
patients/total
Number of S100b positive
patients/total
Number of NSE positive
patients/total
Age at onset
\40 1/4 1/1 1/1 1/1
40–60 47/57 18/19 9/11 11/15
60–80 46/53 18/21 9/9 6/11
[80 2/2 1/1 – –
p-value 0.016 0.76 0.34 0.47
Codon 129
MM 52/65 22/22 7/8 9/12
MV 32/35 11/14 9/10 6/12
VV 2/4 2/2 1/1 2/2
p value 0.075 0.06 0.93 0.25
Disease duration
[median 22/26 10/11 5/5 7/9
\median 48/55 21/21 9/10 8/12
p value 0.74 0.16 0.46 0.58
Time point of LP during disease
a
Early stage 8/8 1/1 1/1 0/1
Middle stage 23/26 7/7 3/3 3/3
Advanced stage 28/34 7/7 3/3 2/2
p value 0.40 – – 0.17
a For the estimation of the disease stage when the LP was performed we divided the individual disease duration in thirds and calculated the time
of lumbar puncture according to the ﬁrst third of the total duration of the disease (early stage), the second (middle) or the third (advanced stage)
of the disease
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1236,000 pg/ml, which is not signiﬁcantly different from what
we found in gCJD patients [21]. These results are con-
cordant with the observation that some gCJD might present
clinical similarities with sporadic CJD [11, 15]. Indeed,
these cases are often misclassiﬁed as sporadic CJD if
family history and genetic testing are not done.
The rate of elevated levels of 14-3-3, tau, NSE and
S100b in genetic CJD was comparable to that observed in
sporadic CJD [3, 20, 26, 27]. In other forms of gTSE, such
as FFI and GSS, these tests were consistently negative.
Although levels of tau in FFI and GSS patients were lower
than the cut-off levels given for CJD, they were still ele-
vated if compared to non-demented controls [24].
The crude analyses of disease modifying factors of the
14-3-3 test in gCJD revealed that age at onset and PRNP
codon 129 genotype inﬂuenced sensitivity. 14-3-3 test
sensitivity was lower in patients with disease onset before
40 years. These data parallel the results performed on
sporadic CJD [20]. However, while in the multivariate
analysis age remained as an independent variable in spo-
radic CJD, in gCJD it did not. Interestingly, in gCJD the
PRNP codon 129 genotype inﬂuences 14-3-3 sensitivity in
a different way with respect to what has been observed in
sporadic CJD. Valine homozygous gCJD patients had a
lower sensitivity in the 14-3-3 test than heterozygous
patients. Though there are too few patients to draw any
deﬁnite conclusions, a possible explanation might be that
the PRNP mutations coupled with the valine alleles
(R208H, D178N, E196K) confer low sensitivity to 14-3-3.
The biological signiﬁcance of brain-derived proteins in
the CSF of patients with TSEs remains to be determined. It
is generally assumed that the release of 14-3-3, tau and
Table 4 CSF biomarker in genetic TSE (reports in the literature)
Author Journal Mutation n 14-3-3 tau nse S100b
E200K
Rosenmann [18] Neurology 1999 E200K 16 94%
Cataldi [4] Neurol Sci 2000 E200K 1 ?
Kovacs [11] Hum Gen 2005 E200K 62 89%
Sanchez-Valle [23] Eur J Neurol 2004 E200K 5 100%
Ladogana [15] Neurology 2005 E200K V210I 95 81% in MM, 95%
in MV ? in VV
V210I
Kovacs [11] Hum Gen 2005 V210I 35 100%
Huang [7] Arq neuropsiquiatr 2001 V210I 1 –
D178N
Zerr [30] Neurology 1998 D178N-129M 8 –
Sanchez-Valle [23] Eur J Neurol 2004 D178N-129M 2 0%
Kovacs [11] Hum Gen 2005 D178N 129V 22 10%
Rosenmann [18] Neurology 1999 D178N 129V 1 ?
Zarranz [29] JNNP 2005 D178N 4 0%
50% 129MM 2
D178N ?MV
Rosenmann [19] Acta Neurol Scand 1998 D178N-129V 2 ?
P102L
Imaiso [8] Rinsho Shinkeigaku 1998 P102L 1 ? Elevated
Kovacs [11] Hum Gen 2005 P102L 7 57%
Others
Krebs [13] Neurogenetics 2005 R148H 1 ?
Iwaski [9] Rinsho Shinkeigaku. 1999 V180I 1 Not done 30
Collins [5] Arch Neurol 2000 T188A 1 ?
Kotta [10] BMC Infect dis 2006 T193I 1 ?
Tumani [25] DMW 2002 E196K 1 ? Elevated Elevated
Capellari [3] Neurology 2005 R208H 1 ?
Roeber [17] Acta Neuropathol 2005 R208H 1 ?
Ladogana [14] Am J Med Gen 2001 E211Q 1 ?
Sanchez-Vallez [22] JNNP 2008 9OPRI 1 -
1626 J Neurol (2009) 256:1620–1628
123NSE proteins in the CSF is a consequence of leakage into
the CSF following rapid neuronal damage. Recently, a
systematic analysis of brain-derived proteins in CSF and
neuropathological lesions has shown that the levels of these
proteins are the consequence of both the degree of neuronal
damage and the localization of the most affected areas [2].
For example NSE levels correlated with damage of sub-
cortical areas (such as the thalamus) and tau protein levels
correlated with the degree of spongiform changes in the
frontal cortex. Our ﬁndings on inverse correlation of tau
levels and the number of octapeptide repeats are of interest,
since the number of repeats has been correlated to the type
of cerebellar PrPSc deposits [28].
In conclusion, the validity of the biomarkers varied
among the different forms of gTSEs. Sensitivity of bio-
markers was high in those forms, which are clinically more
similar to sporadic CJD, such as genetic CJD and insert
gTSEs.
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